Bioidentical, Compounded, or FDA-Approved HRT: What Arizona Telehealth Clinics Can Legally Prescribe

By the Amsara Health team · Clinical review: Mia Chorney, DNP, MSCP · Updated October 2026

Most women who ask for bioidentical hormones can get exactly that from an FDA-approved generic prescription, filled at any pharmacy, for less than the cost of a compounded cream. The marketing of compounded bioidentical hormone therapy has blurred three separate questions: what molecule you take, who makes it, and how the dose is chosen. This article separates them, explains what the professional guidelines and the 2026 regulatory landscape say, and spells out what an Arizona telehealth clinic can legally prescribe and from which pharmacies.

It is written for women who have been told by a friend, a med spa, or an online clinic that pellets or custom creams are the natural choice. Some of those women have a real reason to need a compounded product. Most do not, and the difference matters for safety, cost, and results. For how telehealth hormone care works in Arizona generally, see our pillar guide to HRT telehealth in Arizona.

What does bioidentical actually mean?

A bioidentical hormone is one whose molecular structure is identical to the hormone your body makes. Estradiol is estradiol whether it comes from a patch made by a pharmaceutical manufacturer or a cream mixed in a compounding pharmacy; both are synthesized in a laboratory, usually from plant sterols in soy or wild yam. The term says nothing about who made it, whether it was tested, or how the dose was chosen.

By that definition, a long list of FDA-approved products are bioidentical, as GoodRx’s 2025 review catalogs: estradiol tablets (Estrace and generics), estradiol patches (Climara, Vivelle-Dot, Alora, Dotti, and generics), estradiol gels (Divigel, Elestrin, EstroGel), estradiol spray (Evamist), vaginal estradiol inserts and rings (Vagifem, Yuvafem, Imvexxy, Estring, Femring), micronized progesterone capsules (Prometrium and generics), the combined estradiol-progesterone capsule Bijuva, approved in 2018, and the vaginal DHEA insert Intrarosa. Every one of these was tested in clinical trials, is manufactured under federal quality standards, and carries a label listing its risks.

Non-bioidentical hormones also exist and also work: conjugated equine estrogens (Premarin), synthetic progestins such as medroxyprogesterone and norethindrone, and ethinyl estradiol in some combination products. Many clinicians now prefer bioidentical estradiol and micronized progesterone because of a somewhat better safety signal for progesterone on breast tissue and blood clots, but that is a choice between FDA-approved products, not an argument for compounding.

What is compounded hormone therapy, and who regulates it?

Compounding is the practice of a pharmacist combining or altering ingredients to make a medication for an individual patient. Federal law recognizes two categories, described on the FDA’s compounding page:

• 503A pharmacies compound patient-specific prescriptions and are regulated primarily by state boards of pharmacy. They are not required to meet federal manufacturing standards (cGMP), and their products are not reviewed by the FDA for safety, effectiveness, or quality before dispensing. Most compounded hormone creams, troches, and pellets come from 503A pharmacies.
• 503B outsourcing facilities register with the FDA, must follow cGMP, and may compound in bulk without patient-specific prescriptions from approved bulk-substance or shortage lists. They are inspected by the FDA and are the source of most compounded medications used in hospitals and by larger telehealth practices.

Neither category produces an FDA-approved drug. The difference is oversight: a 503B product is made under federal manufacturing standards; a 503A product’s quality depends on the individual pharmacy and its state board. In 2021, a Drexel University team published a safety comparison in the journal Menopause that illustrates why the distinction matters, which we return to below.

Compounded hormone therapy is also widely used. The most recent national estimate, from a survey presented to the Endocrine Society and cited by the National Academies, put compounded menopausal hormone prescriptions at 26 to 33 million a year in the United States, used by one to 2.5 million women, a volume approaching that of FDA-approved therapy.

What do the National Academies, ACOG, and The Menopause Society say?

All three reached the same conclusion through different processes.

National Academies of Sciences, Engineering, and Medicine (2020)

At the FDA’s request, the National Academies spent two years reviewing the evidence and published The Clinical Utility of Compounded Bioidentical Hormone Therapy on July 1, 2020. The committee found insufficient evidence to support the clinical utility of compounded bioidentical hormone therapy, concluded that marketing claims of superior safety or effectiveness were unsubstantiated, and recommended that prescribers restrict compounded hormones to two situations: a documented allergy to an ingredient in every FDA-approved alternative, or a need for a dosage form that no approved product provides. It also recommended the FDA consider placing bioidentical hormones, with pellets singled out for particular concern, on its list of drugs that are difficult to compound.

The American College of Obstetricians and Gynecologists (2023)

ACOG’s Clinical Consensus No. 6, published in November 2023, states that compounded bioidentical menopausal hormone therapy should not be prescribed routinely when FDA-approved formulations exist, recommends FDA-approved therapy, and concludes that the evidence for using salivary or serum hormone levels to prescribe or adjust doses is limited and not recommended; doses should be adjusted to symptom relief. ACOG also notes that compounded products lack rigorous quality control, with variable absorption, purity, and potency.

The Menopause Society (2022 and ongoing)

The Society’s 2022 Hormone Therapy Position Statement lists the safety concerns with compounded hormone therapy: minimal government regulation and monitoring, overdosing and underdosing, impurities and lack of sterility, lack of efficacy and safety data, and no label outlining risks. Its patient guidance on hormone testing states that it does not recommend custom-compounded products over well-tested, government-approved products for the majority of women, and that saliva testing is not proven accurate or reliable because hormone levels fluctuate throughout the day.

That last point deserves emphasis. The signature of many compounded hormone programs is a saliva or blood test used to design a custom dose. Every major professional body says this is not how hormone therapy should be dosed. The right dose is the one that relieves your symptoms at the lowest effective level, found by starting with a standard dose and adjusting at follow-up, which is exactly what a 6- to 12-week telehealth check-in is for.

What is the problem with hormone pellets?

Pellets are rice-sized cylinders of compressed estradiol or testosterone inserted under the skin of the hip every three to four months. No estradiol pellet has ever been FDA-approved for women; the only approved pellet, Testopel, is a testosterone product approved for men with hypogonadism, as insurer coverage policies such as Aetna’s spell out. Pellets cannot be removed easily once placed, so a dose that turns out to be too high stays too high for months.

The Drexel study published in Menopause in 2021 compared 384 women using compounded pellets with 155 using FDA-approved hormone therapy. Pellet users had serum estradiol and testosterone levels far above the physiologic range (some estradiol levels exceeded 1,000 pg/mL, and peak testosterone averaged 194 ng/dL versus 15.6 ng/dL). Side effects occurred in 57.6% of pellet users versus 14.8% of women on FDA-approved therapy; abnormal uterine bleeding in 55.3% versus 15.2%; breast tenderness in 10.1% versus 2.6%; and hysterectomy in 20.3% versus 6.3%. The Menopause Society’s practice guidance notes that pellets yield marked and prolonged elevation of estradiol and testosterone often far exceeding normal and that the National Academies recommended all compounded pellets as candidates for the difficult-to-compound list.

Pellets also cost $300 to $900 per insertion, or $1,200 to $3,600 a year, almost never covered by insurance. Set that against about $23 a month for a generic estradiol patch that can be removed in two seconds if the dose is wrong.

When is a compounded hormone product the right choice?

There are legitimate cases, and a good clinician recognizes them rather than refusing on principle. Following the National Academies’ criteria, compounding is reasonable when:

• You have a documented allergy or intolerance to an inactive ingredient (an adhesive, a dye, peanut oil in micronized progesterone capsules) present in every FDA-approved option.
• You need a dose or dosage form that does not exist as an approved product, for example a progesterone dose between standard strengths for a woman who cannot tolerate 100 mg.
• The hormone has no FDA-approved product for your indication at all. Testosterone for women is the clearest example: no female testosterone product is approved in the United States, so clinicians use either tiny doses of male products off-label or a compounded low-dose cream. Even here, both the global consensus statement and the ISSWSH guideline prefer approved products at reduced doses. Our testosterone guide covers this in depth.
• A specific FDA-approved product is on national shortage and the compounded version bridges the gap.

In each case the compounded product should come from a pharmacy you and your clinician can vouch for, preferably a 503B outsourcing facility or a 503A pharmacy with independent quality testing, and the decision should be documented. What is not a legitimate reason: a saliva test, a marketing claim that compounded hormones are natural or safer, or a clinic that only sells pellets.

What can an Arizona telehealth clinic legally prescribe, and from where?

Arizona law does not distinguish between compounded and manufactured drugs for telehealth purposes. Under A.R.S. §36-3602, a licensed clinician may prescribe after a telehealth encounter without an in-person examination, except for Schedule II controlled substances. Estradiol and progesterone, approved or compounded, are not controlled. Testosterone is Schedule III and follows federal DEA telemedicine rules in addition.

The regulated party for compounded drugs is the pharmacy. Under A.R.S. §32-1929 and Arizona Administrative Code R4-23-607, any pharmacy located outside Arizona that dispenses or ships prescription drugs into the state must hold a nonresident pharmacy permit from the Arizona State Board of Pharmacy and a current license in its home state, and may dispense to Arizona residents only on a valid prescription. In-state compounding pharmacies are licensed and inspected by the same Board. You can verify any pharmacy’s Arizona permit through the Board’s license lookup.

Practically, this means an Arizona telehealth clinic may send your FDA-approved prescription to any pharmacy, from the CVS down the street to a mail-order pharmacy. A compounded prescription must go to a pharmacy with an Arizona permit, and a careful clinic will tell you which pharmacy it uses and whether it is a 503A or 503B facility. If a telehealth clinic cannot or will not tell you where your compounded hormones are made, that is your answer.

How did the 2025 and 2026 FDA label changes affect this debate?

One of the historical arguments for compounded hormones was that FDA-approved products carried frightening boxed warnings and compounded ones did not. That asymmetry was always misleading, since compounded products simply have no label at all, and it has now largely disappeared. On November 10, 2025, HHS and the FDA announced the removal of the boxed warnings on cardiovascular disease, breast cancer, and probable dementia from menopausal hormone therapy, and on February 12, 2026, the FDA approved the first revised labels across all four product categories, including low-dose vaginal estrogen.

The result is that an FDA-approved estradiol patch now carries an accurate, evidence-based label, is made under federal manufacturing standards, is covered by insurance, costs about $23 a month, and is bioidentical. The case for a compounded alternative has to rest on a specific clinical need, not on the label.

What does this cost in practice?

Option	FDA-approved?	Typical monthly cost (cash)	Insurance coverage	Dose adjustability
Generic estradiol patch	Yes	about $23	Usually low-tier generic	Change patch strength any week
Generic micronized progesterone	Yes	about $15 to $50	Usually low-tier generic	Standard 100 and 200 mg
Bijuva (estradiol + progesterone capsule)	Yes	brand pricing; copay card available	Varies; often tiered	Fixed combinations
Compounded estradiol cream or troche	No (503A or 503B)	about $25 to $75	Rarely	Pharmacy must remake
Compounded progesterone	No	about $20 to $65	Rarely	Pharmacy must remake
Compounded estradiol or testosterone pellets	No	$300 to $900 per insertion, 3 to 4 per year	Essentially never	Cannot be adjusted or easily removed for months

For a full comparison of visit, lab, and medication costs by care model, see How Much Does HRT Cost in Arizona?.

How does Amsara Health approach bioidentical and compounded hormones?

Amsara Health is an Arizona concierge telehealth practice led by Dr. Mia Chorney, DNP, a Menopause Society Certified Practitioner. Amsara prescribes FDA-approved hormone therapy as the default, which for most women means bioidentical estradiol and micronized progesterone. When there is a documented clinical reason for a compounded preparation, Amsara prescribes from licensed 503A and 503B pharmacies holding Arizona permits, and does not dose hormone therapy from saliva tests. Labs are used to establish safety and a metabolic baseline, not to chase a number. If you have been on pellets or custom creams and want a second opinion, the free 15-minute discovery call is the place to start, and our Is HRT Safe? guide covers the evidence you will want to read first.

Frequently asked questions

Sources

• National Academies of Sciences, Engineering, and Medicine. Prescribers should restrict the use of non-FDA-approved compounded bioidentical hormones except for specific medical circumstances (report release). nationalacademies.org, July 1, 2020.
• U.S. Food and Drug Administration. NASEM study on the clinical utility of treating patients with compounded bioidentical hormone replacement therapy. fda.gov.
• American College of Obstetricians and Gynecologists. Compounded Bioidentical Menopausal Hormone Therapy: ACOG Clinical Consensus No. 6. Obstetrics and Gynecology, November 2023 (PubMed).
• The Menopause Society (NAMS). The 2022 Hormone Therapy Position Statement, press release. menopause.org, July 2022.
• The Menopause Society. What is hormone testing? Patient education. menopause.org.
• The North American Menopause Society. Practice Pearl: Compounded Bioidentical Hormone Therapy. menopause.org, December 2020.
• Jiang X, Bossert A, Parthasarathy KN, et al. Safety assessment of compounded non-FDA-approved hormonal therapy versus FDA-approved hormonal therapy in treating postmenopausal women. Menopause, 2021;28(8):867-874.
• MDedge. Hormone pellet safety data not very reassuring for all women (coverage of Jiang et al.). 2021.
• Aetna. Clinical Policy Bulletin 0345: Testosterone pellets and hormone pellet implants. aetna.com, reviewed July 2026.
• U.S. Food and Drug Administration. FD&C Act provisions that apply to human drug compounding (503A and 503B). fda.gov.
• GoodRx. Bioidentical hormone therapy: FDA-approved options and prices. goodrx.com, October 2025.
• CompoundingFinder. Compounded BHRT Cost Guide and Hormone Pellet Therapy Cost (industry estimates). 2026.
• U.S. Department of Health and Human Services. HHS Advances Women’s Health, Removes Misleading FDA Warnings on Hormone Replacement Therapy. hhs.gov, November 10, 2025.
• U.S. Food and Drug Administration. FDA Approves Labeling Changes for Menopausal Hormone Therapy Products. fda.gov, February 12, 2026.
• Arizona State Legislature. A.R.S. 36-3602: Delivery of health care through telehealth; requirements; exceptions. azleg.gov.
• Arizona State Legislature. A.R.S. 32-1929: Pharmacy permits; nonresident pharmacies. azleg.gov.
• Arizona Administrative Code R4-23-607: Nonresident Permits (Arizona State Board of Pharmacy). Cornell LII.
• Healio. Number of unregulated compounded menopausal hormone therapy prescriptions nears FDA-approved (Pinkerton and Constantine survey). 2015; cited by NASEM 2020.

This article is for educational purposes and is not a substitute for individual medical advice. Talk with a licensed provider about your specific situation.

---

On pellets or custom creams and want a second opinion?

Unhurried appointments, advanced diagnostics, and a plan built for you.

Already a patient? Visit your Amsara Patient Portal →